Investment Analysts’ Weekly Ratings Changes for BioLife Solutions (BLFS)

Share on StockTwits

BioLife Solutions (NASDAQ: BLFS) has recently received a number of price target changes and ratings updates:

  • 11/29/2019 – BioLife Solutions was upgraded by analysts at TheStreet from a “c” rating to a “b-” rating.
  • 11/25/2019 – BioLife Solutions was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “BioLife Solutions has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on their proprietary bio-packaging technology and a patented understanding of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today. “
  • 11/25/2019 – BioLife Solutions was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 11/23/2019 – BioLife Solutions was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 11/20/2019 – BioLife Solutions is now covered by analysts at Oppenheimer Holdings Inc.. They set an “outperform” rating and a $22.00 price target on the stock.
  • 11/14/2019 – BioLife Solutions was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 11/14/2019 – BioLife Solutions was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $16.00 price target on the stock. According to Zacks, “BioLife Solutions has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on their proprietary bio-packaging technology and a patented understanding of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today. “
  • 11/14/2019 – BioLife Solutions was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 11/7/2019 – BioLife Solutions was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 10/30/2019 – BioLife Solutions was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “BioLife Solutions has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on their proprietary bio-packaging technology and a patented understanding of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today. “
  • 10/29/2019 – BioLife Solutions was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $20.00 price target on the stock. According to Zacks, “BioLife Solutions has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on their proprietary bio-packaging technology and a patented understanding of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today. “
  • 10/25/2019 – BioLife Solutions was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 10/18/2019 – BioLife Solutions was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “BioLife Solutions has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on their proprietary bio-packaging technology and a patented understanding of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today. “
  • 10/18/2019 – BioLife Solutions was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 10/17/2019 – BioLife Solutions was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $18.00 price target on the stock. According to Zacks, “BioLife Solutions has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on their proprietary bio-packaging technology and a patented understanding of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today. “
  • 10/12/2019 – BioLife Solutions was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.

BioLife Solutions stock traded down $0.15 on Thursday, hitting $16.07. 119,975 shares of the stock traded hands, compared to its average volume of 174,041. BioLife Solutions Inc has a 1 year low of $9.15 and a 1 year high of $22.44. The firm has a market cap of $328.66 million, a P/E ratio of 114.79, a price-to-earnings-growth ratio of 20.94 and a beta of 1.33. The company has a current ratio of 6.49, a quick ratio of 5.33 and a debt-to-equity ratio of 0.01. The business’s fifty day simple moving average is $16.55 and its 200 day simple moving average is $17.65.

In other news, VP James Mathers sold 2,500 shares of BioLife Solutions stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $16.27, for a total transaction of $40,675.00. Following the completion of the transaction, the vice president now directly owns 19,884 shares in the company, valued at $323,512.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Casdin Partners Master Fund, L bought 20,000 shares of the stock in a transaction dated Tuesday, November 19th. The shares were acquired at an average price of $15.15 per share, with a total value of $303,000.00. The disclosure for this purchase can be found here. Insiders sold a total of 169,794 shares of company stock worth $3,092,142 over the last ninety days. Insiders own 27.00% of the company’s stock.

A number of hedge funds have recently bought and sold shares of BLFS. JPMorgan Chase & Co. bought a new stake in BioLife Solutions during the 2nd quarter valued at about $30,000. Alpine Woods Capital Investors LLC bought a new stake in shares of BioLife Solutions during the second quarter valued at approximately $170,000. Morgan Stanley increased its position in shares of BioLife Solutions by 17.5% during the second quarter. Morgan Stanley now owns 11,506 shares of the medical equipment provider’s stock valued at $195,000 after acquiring an additional 1,713 shares in the last quarter. Menta Capital LLC bought a new stake in shares of BioLife Solutions during the second quarter valued at approximately $202,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in BioLife Solutions in the 2nd quarter worth approximately $283,000. 50.22% of the stock is owned by institutional investors.

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Recommended Story: How big is the FinTech market?

Receive News & Ratings for BioLife Solutions Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

FormulaFolio Investments LLC Sells 110 Shares of Norfolk Southern Corp.
FormulaFolio Investments LLC Sells 110 Shares of Norfolk Southern Corp.
1,337 Shares in Huntington Ingalls Industries Inc  Acquired by FormulaFolio Investments LLC
1,337 Shares in Huntington Ingalls Industries Inc Acquired by FormulaFolio Investments LLC
FormulaFolio Investments LLC Boosts Position in iShares Russell 1000 Value ETF
FormulaFolio Investments LLC Boosts Position in iShares Russell 1000 Value ETF
FormulaFolio Investments LLC Buys New Shares in Pentair PLC
FormulaFolio Investments LLC Buys New Shares in Pentair PLC
FormulaFolio Investments LLC Buys New Holdings in Steel Dynamics, Inc.
FormulaFolio Investments LLC Buys New Holdings in Steel Dynamics, Inc.
FormulaFolio Investments LLC Acquires 184 Shares of Vanguard Information Technology ETF
FormulaFolio Investments LLC Acquires 184 Shares of Vanguard Information Technology ETF


 
© 2006-2020 Zolmax.